Intended Retirement of Independent Non-executive Director and changes of composition of board committees
MWN-AI** Summary
HUTCHMED (China) Limited announced the retirement of Professor Mok Shu Kam, Tony, who has served as an Independent Non-executive Director for over eight years. With his decision not to seek re-election at the upcoming annual general meeting (AGM) scheduled for May 12, 2026, he will officially step down from the Board at the conclusion of this meeting. Professor Mok's tenure approaches the nine-year limit stipulated by the Hong Kong Listing Rules.
Upon his retirement, he will also resign from his roles as chairman and member of various board committees. In preparation for this shift, the Board has approved several changes in committee leadership that will take effect following the AGM, pending the re-election of the respective Directors. Dr. Renu Bhatia will be appointed as the Senior and Lead Independent Non-executive Director and will also take over as the chairman of the Nomination Committee. Dr. Chaohong Hu will become the chairman of the Technical Committee, and Professor Tan Shao Weng, Daniel will join the Sustainability Committee as a member.
Dr. Dan Eldar, Chairman of HUTCHMED, praised Professor Mok for his distinguished service, noting his significant contributions to the Company’s board composition and its scientific and clinical development programs. He emphasized the invaluable expertise Mok brought to the Company’s long-term strategy, particularly in the field of oncology.
Mok confirmed that he has no disagreements with the Board and there are no additional matters to disclose to shareholders regarding his retirement. HUTCHMED remains committed to the discovery and global commercialization of innovative cancer therapies.
MWN-AI** Analysis
HUTCHMED's announcement regarding Professor Mok Shu Kam's impending retirement as an Independent Non-executive Director marks a significant transition for the company. With Professor Mok stepping down after nearly nine years of service—close to the limit imposed by the Hong Kong Listing Rules—investors should carefully evaluate the implications of this leadership change on HUTCHMED’s strategic direction and operational stability.
The appointment of Dr. Renu Bhatia as the new Senior and Lead Independent Non-executive Director suggests a planned continuity in governance. Dr. Bhatia’s leadership of the Nomination Committee signals an intention to maintain a diverse and competent board, essential for navigating the complexities of the biopharmaceutical industry. In contrast, Dr. Chaohong Hu's chairmanship of the Technical Committee and Professor Tan Shao Weng's addition to the Sustainability Committee reflect a strategic emphasis on scientific rigor and corporate responsibility.
Investors should note that transitions like these can lead to both opportunities and risks. HUTCHMED's management emphasized the importance of Professor Mok’s contributions in guiding the company’s strategic vision, particularly in oncology. This raises questions about whether the newly configured board will maintain, if not surpass, the momentum generated during Professor Mok's tenure.
Moreover, with the company actively pursuing innovative therapies for cancer and immunological diseases, the success of HUTCHMED's ongoing projects should remain a focal point for investors. Forward-looking statements within the announcement caution against assuming seamless continuity; potential management difficulties or the challenges of integrating new directors can affect operational efficacy.
In conclusion, while the board's restructuring presents risks, it also opens avenues for innovation and growth. Investors should monitor subsequent developments closely and consider HUTCHMED’s overall strategic direction amid these changes before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:?HCM, HKEX:?13) today announces that Professor Mok Shu Kam, Tony has informed the Company that he would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 12, 2026 (“AGM”). Professor Mok has served as an Independent Non-executive Director of the Company for more than eight years, approaching the nine-year cap on the tenure of independent non-executive directors under the Hong Kong Listing Rules. Consequently, he will cease to be an Independent Non-executive Director of the Company at the conclusion of the AGM. Upon his retirement, he will also step down from his roles as chairman and member of the board committees of the Company.
In connection with the intended retirement of Professor Mok from the Board, the Board has approved the following changes to the composition of the board committees and the Senior and Lead Independent Non-executive Director of the Company, effective from the conclusion of the AGM, subject to the respective Directors being re-elected as Directors by the shareholders at the AGM:
(1) Dr Renu Bhatia will be appointed as the Senior and Lead Independent Non-executive Director, and appointed on the Nomination Committee as the chairman;
(2) Dr Chaohong Hu will be appointed as the chairman of the Technical Committee; and
(3) Professor Tan Shao Weng, Daniel will be appointed as a member of the Sustainability Committee.
Each of Dr Bhatia, Dr Hu and Professor Tan is currently an Independent Non-executive Director of the Company.
Dr Dan Eldar, the Chairman of HUTCHMED, said: “Professor Mok has served with distinction as an Independent Non-executive Director and as chairman of both the Nomination Committee and the Technical Committee. His leadership has been instrumental in strengthening the Board composition, and guiding the scientific and clinical development programs. His internationally recognized expertise in oncology has brought invaluable perspective to the long term strategy of the Company. The Board sincerely thanks Professor Mok for his significant contributions to the growth of the Company, and we wish him all the best in his future endeavours.”
Pursuant to the requirements of Rule 13.51(2) of the Hong Kong Listing Rules, Professor Mok has confirmed that he has no disagreement with the Board and that there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with his retirement from the Board.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch?med.com or follow us on LinkedIn.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, the risk that current or future appointees to HUTCHMED’s board of directors are not e?ective in their respective positions, the di?iculty in locating and recruiting suitable candidates for its board of directors and the management di?iculties which may arise from changes in HUTCHMED’s board of directors. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, on A?M and with The Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |
FAQ**
How does HUTCHMED (China) Limited HCM plan to mitigate potential risks associated with changes in board composition following Professor Mok's retirement?
What strategies does HUTCHMED (China) Limited HCM have in place to attract top talent to its board and committees, especially after recent leadership changes?
How might the change in board leadership at HUTCHMED (China) Limited HCM impact its strategic direction in the biopharmaceutical sector in Hong Kong and Shanghai?
What is the significance of Professor Mok's contributions to HUTCHMED (China) Limited HCM as an Independent Non-executive Director, particularly in relation to oncology development in China?
**MWN-AI FAQ is based on asking OpenAI questions about HUTCHMED (China) Limited (NASDAQ: HCM).
NASDAQ: HCM
HCM Trading
0.07% G/L:
$13.84 Last:
14,358 Volume:
$13.67 Open:
